Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum.

Antibodies, Neutralizing Antibodies, Viral COVID-19 / prevention & control Humans Neutralization Tests SARS-CoV-2 / genetics South Africa Viral Vaccines
BA.4 BA.5 COVID-19 Omicron SARS-CoV-2 VoC antibody escape variant

Journal

Cell
ISSN: 1097-4172
Titre abrégé: Cell
Pays: United States
ID NLM: 0413066

Informations de publication

Date de publication:
07 07 2022
Historique:
received: 06 05 2022
revised: 23 05 2022
accepted: 03 06 2022
pubmed: 1 7 2022
medline: 14 7 2022
entrez: 30 6 2022
Statut: ppublish

Résumé

The Omicron lineage of SARS-CoV-2, which was first described in November 2021, spread rapidly to become globally dominant and has split into a number of sublineages. BA.1 dominated the initial wave but has been replaced by BA.2 in many countries. Recent sequencing from South Africa's Gauteng region uncovered two new sublineages, BA.4 and BA.5, which are taking over locally, driving a new wave. BA.4 and BA.5 contain identical spike sequences, and although closely related to BA.2, they contain further mutations in the receptor-binding domain of their spikes. Here, we study the neutralization of BA.4/5 using a range of vaccine and naturally immune serum and panels of monoclonal antibodies. BA.4/5 shows reduced neutralization by the serum from individuals vaccinated with triple doses of AstraZeneca or Pfizer vaccine compared with BA.1 and BA.2. Furthermore, using the serum from BA.1 vaccine breakthrough infections, there are, likewise, significant reductions in the neutralization of BA.4/5, raising the possibility of repeat Omicron infections.

Identifiants

DOI: 10.1016/j.cell.2022.06.005 PMID: 35772405 PMC: PMC9181312
pubmed: 35772405
pii: S0092-8674(22)00710-3
doi: 10.1016/j.cell.2022.06.005
pmc: PMC9181312
pii:
doi:

Substances chimiques

Antibodies, Neutralizing 0
Antibodies, Viral 0
Viral Vaccines 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2422-2433.e13

Subventions

Organisme : Wellcome Trust
ID : 203224/Z/16/Z
Pays : United Kingdom
Organisme : Wellcome Trust
ID : WT109965MA
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/V001329/1
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 090532/Z/09/Z
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 101122/Z/13/Z
Pays : United Kingdom
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Department of Health
ID : NIHR300791
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/L006588/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_PC_19059
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 203141/Z/16/Z
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/N00065X/1
Pays : United Kingdom

Investigateurs

Christopher Conlon (C)
Alexandra Deeks (A)
John Frater (J)
Lisa Frending (L)
Siobhan Gardiner (S)
Anni Jämsén (A)
Katie Jeffery (K)
Tom Malone (T)
Eloise Phillips (E)
Lucy Rothwell (L)
Lizzie Stafford (L)

Informations de copyright

Copyright © 2022 The Author(s). Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests G.R.S. sits on the GSK Vaccines Scientific Advisory Board and is a founding member of RQ Biotechnology. Oxford University holds intellectual property related to the Oxford-AstraZeneca vaccine and SARS-CoV-2 mAb discovered in G.R.S.’s laboratory. A.J.P. is Chair of UK Dept. health and Social Care’s (DHSC) Joint Committee on Vaccination & Immunisation (JCVI) but does not participate in the JCVI COVID-19 committee and is a member of the WHO’s SAGE. The views expressed in this article do not necessarily represent the views of DHSC, JCVI, or WHO. The University of Oxford has entered into a partnership with AstraZeneca on coronavirus vaccine development. T.L. is named as an inventor on a patent application covering this SARS-CoV-2 vaccine and was a consultant to Vaccitech for an unrelated project while the study was conducted. S.J.D. is a scientific advisor to the Scottish Parliament on COVID-19.

Références

Nat Microbiol. 2021 Sep;6(9):1188-1198
pubmed: 34400835
Nature. 2022 Feb;602(7898):654-656
pubmed: 35016196
Cell. 2021 Apr 15;184(8):2183-2200.e22
pubmed: 33756110
Cell Host Microbe. 2021 May 12;29(5):819-833.e7
pubmed: 33789084
Cell Host Microbe. 2020 Sep 9;28(3):445-454.e6
pubmed: 32585135
Proc Natl Acad Sci U S A. 2017 Oct 17;114(42):11157-11162
pubmed: 29073020
Cell. 2021 Aug 5;184(16):4220-4236.e13
pubmed: 34242578
Cell Host Microbe. 2022 Jan 12;30(1):53-68.e12
pubmed: 34921776
Nat Microbiol. 2021 Oct;6(10):1233-1244
pubmed: 34548634
Acta Crystallogr D Struct Biol. 2018 Feb 1;74(Pt 2):85-97
pubmed: 29533234
Nature. 2020 May;581(7807):215-220
pubmed: 32225176
Lancet. 2021 Sep 11;398(10304):981-990
pubmed: 34480858
Cell. 2021 May 27;184(11):2939-2954.e9
pubmed: 33852911
Science. 2020 Mar 13;367(6483):1260-1263
pubmed: 32075877
Science. 2020 Aug 28;369(6507):1119-1123
pubmed: 32661058
Lancet. 2020 Aug 15;396(10249):467-478
pubmed: 32702298
Acta Crystallogr D Biol Crystallogr. 2006 Oct;62(Pt 10):1243-50
pubmed: 17001101
Nature. 2020 Jul;583(7815):290-295
pubmed: 32422645
Vet Res. 2010 Nov-Dec;41(6):38
pubmed: 20167200
Bio Protoc. 2021 Nov 05;11(21):e4236
pubmed: 34859134
Science. 2021 Aug 6;373(6555):
pubmed: 34168071
Cell Host Microbe. 2022 Feb 9;30(2):154-162.e5
pubmed: 35120605
Science. 2020 Aug 7;369(6504):650-655
pubmed: 32571838
Cell. 2021 May 13;184(10):2605-2617.e18
pubmed: 33831372
Proc Natl Acad Sci U S A. 2022 Jul 19;119(29):e2205784119
pubmed: 35767670
Cell. 2020 Apr 16;181(2):281-292.e6
pubmed: 32155444
Antib Ther. 2020 Nov 24;3(4):246-256
pubmed: 33912795
Cell. 2022 Feb 3;185(3):467-484.e15
pubmed: 35081335
Nat Struct Mol Biol. 2020 Sep;27(9):846-854
pubmed: 32661423
Science. 2020 May 8;368(6491):630-633
pubmed: 32245784
Cell. 2021 Apr 29;184(9):2348-2361.e6
pubmed: 33730597
Acta Crystallogr D Biol Crystallogr. 2010 Apr;66(Pt 4):486-501
pubmed: 20383002
Nat Struct Mol Biol. 2020 Oct;27(10):950-958
pubmed: 32737466
Proc Natl Acad Sci U S A. 2021 Jun 22;118(25):
pubmed: 34083352
N Engl J Med. 2021 Jan 21;384(3):238-251
pubmed: 33332778
Cell. 2021 Apr 15;184(8):2201-2211.e7
pubmed: 33743891
Cell. 2022 Jun 9;185(12):2116-2131.e18
pubmed: 35662412
J Mol Biol. 1979 Oct 15;134(1):109-42
pubmed: 537059
Acta Crystallogr D Struct Biol. 2019 Oct 1;75(Pt 10):861-877
pubmed: 31588918
Emerg Microbes Infect. 2020 Dec;9(1):680-686
pubmed: 32207377
Nat Commun. 2022 Aug 10;13(1):4686
pubmed: 35948557
Protein Expr Purif. 2008 Nov;62(1):83-9
pubmed: 18662785
Nature. 2020 Dec;588(7839):682-687
pubmed: 33045718
Lancet. 2022 Jan 29;399(10323):412-413
pubmed: 35065007
Biochemistry. 1988 Aug 23;27(17):6262-8
pubmed: 2851319
Nature. 2021 Apr;592(7853):277-282
pubmed: 33545711
J Appl Crystallogr. 2007 Aug 1;40(Pt 4):658-674
pubmed: 19461840
RNA. 2003 Apr;9(4):493-501
pubmed: 12649500
Science. 2022 Feb 25;375(6583):864-868
pubmed: 35076256

Auteurs

Aekkachai Tuekprakhon (A)

Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.

Rungtiwa Nutalai (R)

Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.

Aiste Dijokaite-Guraliuc (A)

Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.

Daming Zhou (D)

Division of Structural Biology, Nuffield Department of Medicine, University of Oxford, The Wellcome Centre for Human Genetics, Oxford, UK; Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), University of Oxford, Oxford, UK.

Helen M Ginn (HM)

Diamond Light Source Ltd, Harwell Science & Innovation Campus, Didcot, UK.

Muneeswaran Selvaraj (M)

Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.

Chang Liu (C)

Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK; Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), University of Oxford, Oxford, UK.

Alexander J Mentzer (AJ)

Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK; Oxford University Hospitals NHS Foundation Trust, Oxford, UK.

Piyada Supasa (P)

Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.

Helen M E Duyvesteyn (HME)

Division of Structural Biology, Nuffield Department of Medicine, University of Oxford, The Wellcome Centre for Human Genetics, Oxford, UK.

Raksha Das (R)

Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.

Donal Skelly (D)

Oxford University Hospitals NHS Foundation Trust, Oxford, UK; Peter Medawar Building for Pathogen Research, Oxford, UK; Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.

Thomas G Ritter (TG)

Oxford University Hospitals NHS Foundation Trust, Oxford, UK.

Ali Amini (A)

Oxford University Hospitals NHS Foundation Trust, Oxford, UK; Peter Medawar Building for Pathogen Research, Oxford, UK; Translational Gastroenterology Unit, University of Oxford, Oxford, UK.

Sagida Bibi (S)

Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.

Sandra Adele (S)

Oxford University Hospitals NHS Foundation Trust, Oxford, UK.

Sile Ann Johnson (SA)

Oxford University Hospitals NHS Foundation Trust, Oxford, UK.

Bede Constantinides (B)

Nuffield Department of Medicine, University of Oxford, Oxford, UK.

Hermione Webster (H)

Nuffield Department of Medicine, University of Oxford, Oxford, UK.

Nigel Temperton (N)

Viral Pseudotype Unit, Medway School of Pharmacy, University of Kent and Greenwich Chatham Maritime, Kent, UK.

Paul Klenerman (P)

Oxford University Hospitals NHS Foundation Trust, Oxford, UK; Peter Medawar Building for Pathogen Research, Oxford, UK; Translational Gastroenterology Unit, University of Oxford, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK.

Eleanor Barnes (E)

Oxford University Hospitals NHS Foundation Trust, Oxford, UK; Peter Medawar Building for Pathogen Research, Oxford, UK; Translational Gastroenterology Unit, University of Oxford, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK.

Susanna J Dunachie (SJ)

Oxford University Hospitals NHS Foundation Trust, Oxford, UK; Peter Medawar Building for Pathogen Research, Oxford, UK; Centre For Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK; Mahidol-Oxford Tropical Medicine Research Unit, Department of Medicine, University of Oxford, Oxford, UK.

Derrick Crook (D)

Nuffield Department of Medicine, University of Oxford, Oxford, UK.

Andrew J Pollard (AJ)

Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK.

Teresa Lambe (T)

Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), University of Oxford, Oxford, UK; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.

Philip Goulder (P)

Peter Medawar Building for Pathogen Research, Oxford, UK; Department of Paediatrics, University of Oxford, Oxford, UK.

Neil G Paterson (NG)

Diamond Light Source Ltd, Harwell Science & Innovation Campus, Didcot, UK.

Mark A Williams (MA)

Diamond Light Source Ltd, Harwell Science & Innovation Campus, Didcot, UK.

David R Hall (DR)

Diamond Light Source Ltd, Harwell Science & Innovation Campus, Didcot, UK.

Elizabeth E Fry (EE)

Division of Structural Biology, Nuffield Department of Medicine, University of Oxford, The Wellcome Centre for Human Genetics, Oxford, UK. Electronic address: liz@strubi.ox.ac.uk.

Jiandong Huo (J)

Division of Structural Biology, Nuffield Department of Medicine, University of Oxford, The Wellcome Centre for Human Genetics, Oxford, UK. Electronic address: dongdong.imm.ox.ac.uk@gmail.com.

Juthathip Mongkolsapaya (J)

Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK; Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), University of Oxford, Oxford, UK. Electronic address: juthathip.mongkolsapaya@well.ox.ac.uk.

Jingshan Ren (J)

Division of Structural Biology, Nuffield Department of Medicine, University of Oxford, The Wellcome Centre for Human Genetics, Oxford, UK. Electronic address: ren@strubi.ox.ac.uk.

David I Stuart (DI)

Division of Structural Biology, Nuffield Department of Medicine, University of Oxford, The Wellcome Centre for Human Genetics, Oxford, UK; Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), University of Oxford, Oxford, UK; Diamond Light Source Ltd, Harwell Science & Innovation Campus, Didcot, UK. Electronic address: dave@strubi.ox.ac.uk.

Gavin R Screaton (GR)

Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK; Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), University of Oxford, Oxford, UK. Electronic address: gavin.screaton@medsci.ox.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps neutralisants › Antibody escape of SARS-CoV-2 Omicron BA.4 and...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps antiviraux › Antibody escape of SARS-CoV-2 Omicron BA.4 and...
questionsmedicales.fr › Maladies de l'appareil respiratoire › Infections de l'appareil respiratoire › Pneumopathie infectieuse › Pneumopathie virale › COVID-19 › Antibody escape of SARS-CoV-2 Omicron BA.4 and...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Antibody escape of SARS-CoV-2 Omicron BA.4 and...
questionsmedicales.fr › Techniques d'investigation › Techniques immunologiques › Tests immunologiques › Tests sérologiques › Tests de neutralisation › Antibody escape of SARS-CoV-2 Omicron BA.4 and...
questionsmedicales.fr › Virus › Virus à ARN › Virus à ARN à brin positif › Nidovirales › Coronaviridae › Coronavirus › Betacoronavirus › Virus du SRAS › SARS-CoV-2 › Antibody escape of SARS-CoV-2 Omicron BA.4 and...
questionsmedicales.fr › Régions géographiques › Afrique › Afrique subsaharienne › Afrique australe › République d'Afrique du Sud › Antibody escape of SARS-CoV-2 Omicron BA.4 and...
questionsmedicales.fr › Mélanges complexes › Produits biologiques › Vaccins › Vaccins antiviraux › Antibody escape of SARS-CoV-2 Omicron BA.4 and...